When she lost her father, it wasn’t just a personal tragedy—it was a breaking point.
This is the story of Micaela, the co-founder of Metanova (Bittensor subnet 68).
Micaela’s father had defied every odd. Diagnosed with stage 2 pancreatic cancer, given a 7% chance of surviving beyond a year, yet he fought through three surgeries, three rounds of chemotherapy, and endless screenings. For a while, it seemed like he had won. His remission was proof that the mind and body, when treated together, could beat the statistics.
But the very treatment that was supposed to save him—chemo—became the silent thief that took his life through the complications. It wasn’t science’s fault alone; it was the system’s. The economic incentives that drive drug development are deeply broken. Innovation has slowed to a crawl. Pharma spends billions chasing safer bets, while millions die waiting for breakthroughs that never come.
That realization lit a fire. If the system can’t fix itself, maybe the network can.
In 2023, from hospital waiting rooms and ICU corridors, Micaela began taking calls with her co-founder, @pennapdr. Those early conversations became the foundation for Metanova Labs—a decentralized drug discovery platform built on Bittensor.
Their mission wasn’t just to make better drugs. It was to realign the very incentives behind discovery itself—to use crypto and AI to create an open, collaborative, and decentralized system for developing chem tech that expands human life and experience.
Metanova isn’t just another biotech startup. It’s an act of defiance. A belief that we can build a world where discovery is permissionless, where life-saving innovation isn’t trapped behind patents or profit margins, and where the next cure might come not from a boardroom, but from a subnet.
Powered by Bittensor’s decentralized intelligence network, Metanova (SN68) brings together researchers, developers, and AI agents to model, simulate, and evolve small molecules in ways that traditional pharma pipelines can’t—or won’t.
It’s the future of drug discovery, rebuilt from the ground up. A network born from loss, powered by belief, and driven by the conviction that when science fails, we build again.
🧬 “Together, we’re raising the bar for drug discovery—building the infrastructure for a new kind of tech, and a new class of medicines.” — Micaela, CEO of Metanova Labs.
Be the first to comment